Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

10.85USD
23 Apr 2018
Change (% chg)

$-0.15 (-1.36%)
Prev Close
$11.00
Open
$11.10
Day's High
$11.30
Day's Low
$10.77
Volume
190,433
Avg. Vol
97,396
52-wk High
$29.00
52-wk Low
$10.50

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.68
Market Cap(Mil.): $345.87
Shares Outstanding(Mil.): 31.44
Dividend: --
Yield (%): --

Financials

  PRTK.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.36 -- --
ROI: -67.93 -0.74 13.19
ROE: -115.62 -2.80 15.00

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

Apr 19 2018

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

Apr 18 2018

BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors

* PARATEK APPOINTS ROLF K. HOFFMAN TO COMPANY’S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 13 2018

BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA

* PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA

Apr 04 2018

BRIEF-Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78

* PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019

Mar 01 2018

BRIEF-Paratek Completes Submission Of New Drug Applications To U.S.FDA

* PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Paratek Announces $50.0 Mln Public Offering Of Common Stock

* PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

Jan 17 2018

BRIEF-Paratek Provides Update On Pipeline Progress

* PARATEK PHARMACEUTICALS - HAS EARNED A $5 MILLION MILESTONE PAYMENT FROM ALLERGAN FOR DEVELOPMENT OF SEYSARA Source text for Eikon: Further company coverage:

Jan 03 2018

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

Dec 01 2017

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

Nov 08 2017

Earnings vs. Estimates